Fury as Australia appoints former industry lobbyist to drugs watchdogBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7283.383/a (Published 17 February 2001) Cite this as: BMJ 2001;322:383
- Christopher Zinn
The federal government in Australia is being widely condemned at home and abroad for its shake-up of its pharmaceutical advisory board and the controversial appointment of a former drug industry lobbyist.
The federal health minister, Michael Wooldridge, has come under fire for his elevation of drug company executive Pat Clear to the government's Pharmaceutical Benefits Advisory Committee.
The 12 member committee recommends which drugs qualify for subsidies under the nation's £1.5bn (US$2.25bn) pharmaceutical benefits scheme and has recently seen the government legislate to remove several senior members.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial